Poor earnings, but not entirely unexpected I think
My longer term thoughts are that the FDA Acquired Brain Injury designation approval will reinforce Jack's efforts at getting network healthcare provider deals. Likewise on the industrial side, Ekso's tweet about their injury reduction % numbers via FORD's pilot program make me think larger scale buys might happen for Ekso Vest.
Poor numbers for the quarter mean less to me than a good overall position in the market and a growth trajectory that makes sense. Are other exoskeleton companies doing any better right now?
News 
Market Data 
Discover 
